Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Xenazine Model: Big Things Come In Small Packages

Executive Summary

The Huntington's chorea therapy Xenazine (tetrabenazine) is being used by just over 1,000 patients after three months on the market, and Biovail couldn't be happier

You may also be interested in...



Non-Profit CHDI Taps Galapagos For Developing Huntington's Disease Therapy

The philanthropy firm, like others of its ilk, seeks to accelerate early-stage R&D on a neglected disease.

Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010

Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them

Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010

Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them

Related Content

Topics

UsernamePublicRestriction

Register

PS050828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel